Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure

被引:12
作者
Manickam, Manoj [1 ]
Jalani, Hitesh B. [1 ]
Pillaiyar, Thanigaimalai [1 ]
Sharma, Niti [1 ]
Boggu, Pulla Reddy [1 ]
Venkateswararao, Eeda [1 ]
Lee, You-Jung [2 ]
Jeon, Eun-Seok [2 ]
Jung, Sang-Hun [1 ]
机构
[1] Chungnam Natl Univ, Inst Drug Res & Dev, Coll Pharm, Daejeon 34134, South Korea
[2] Sungkyunkwan Univ, Div Cardiol, Samsung Med Ctr, Samsung Biomed Res Inst,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea
基金
新加坡国家研究基金会;
关键词
Flexible urea; Cardiac myosin activator; Inotrope; Systolic heart failure; OMECAMTIV-MECARBIL; GLOBAL BURDEN; MUSCLE MYOSIN; RECEPTOR; PHOSPHORYLATION; LEVOSIMENDAN; FLEXIBILITY; INHIBITORS; INOTROPES; MORTALITY;
D O I
10.1016/j.ejmech.2017.04.005
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of flexible urea derivatives have been synthesized and demonstrated as selective cardiac myosin ATPase activator. Among them 1-phenethyl-3-(3-phenylpropyl)urea (1, cardiac myosin ATPase activation at 10) mu M = 51.1%; FS = 18.90; EF = 12.15) and 1-benzyl-3-(3-phenylpropyl)urea (9, cardiac myosin ATPase activation = 53.3%; FS = 30.04; EF = 18.27) showed significant activity in vitro and in vivo. The change of phenyl ring with tetrahydropyran-4-yl moiety viz., 1-(3-phenylpropy1)-3-((tetrahydro-2H-pyran-4-y1) methyl)urea (14, cardiac myosin ATPase activation = 81.4%; FS = 20.50; EF = 13.10), and morpholine moiety viz., 1-(2-morpholinoethyl)-3-(3-phenylpropyl)urea (21, cardiac myosin ATPase activation = 44.0%; FS = 24.79; EF = 15.65), proved to be efficient to activate the cardiac myosin. The potent compounds 1, 9, 14 and 21 were found to be selective for cardiac myosin over skeletal and smooth myosins. Thus, these urea derivatives are potent scaffold to develop as a newer cardiac myosin activator for the treatment of systolic heart failure. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:379 / 391
页数:13
相关论文
共 40 条
[1]   Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000, cases in the Acute Decompensated Heart Failure National Registry (ADHERE) [J].
Adams, KF ;
Fonarow, GC ;
Emerman, CL ;
LeJemtel, TH ;
Costanzo, MR ;
Abraham, WT ;
Berkowitz, RL ;
Galvao, M ;
Horton, DP .
AMERICAN HEART JOURNAL, 2005, 149 (02) :209-216
[2]  
[Anonymous], [No title captured], Patent No. [6495337 B1, 6495337]
[3]   Blood-brain barrier penetration by two dermorphin tetrapeptide analogues:: Role of lipophilicity vs structural flexibility [J].
Ballet, Steven ;
Misicka, Aleksandra ;
Kosson, Piotr ;
Lemieux, Carole ;
Chung, Nga N. ;
Schiller, Peter W. ;
Lipkowski, Andrzej W. ;
Tourwe, Dirk .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (08) :2571-2574
[4]   β-adrenergic receptor blockade in chronic heart failure [J].
Bristow, MR .
CIRCULATION, 2000, 101 (05) :558-569
[6]   EFFECT OF PHOSPHORYLATION OF SMOOTH-MUSCLE MYOSIN ON ACTIN ACTIVATION AND CA2+ REGULATION [J].
CHACKO, S ;
CONTI, MA ;
ADELSTEIN, RS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (01) :129-133
[7]   A Novel Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents Doxorubicin-induced Cardiotoxicity in Rats [J].
Chang, Sung-A ;
Lim, Byung-Kwan ;
Lee, You Jung ;
Hong, Mi-Kyung ;
Choi, Jin-Oh ;
Jeon, Eun-Seok .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2015, 30 (05) :559-568
[8]   A small-molecule inhibitor of skeletal muscle myosin II [J].
Cheung, A ;
Dantzig, JA ;
Hollingworth, S ;
Baylor, SM ;
Goldman, YE ;
Mitchison, TJ ;
Straight, AF .
NATURE CELL BIOLOGY, 2002, 4 (01) :83-88
[9]   Impact of linker strain and flexibility in the design of a fragment-based inhibitor [J].
Chung, Suhman ;
Parker, Jared B. ;
Bianchet, Mario ;
Amzel, L. Mario ;
Stivers, James T. .
NATURE CHEMICAL BIOLOGY, 2009, 5 (06) :407-413
[10]   The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial [J].
Cleland, John G. F. ;
Teerlink, John R. ;
Senior, Roxy ;
Nifontov, Evgeny M. ;
Mc Murray, John J. V. ;
Lang, Chim C. ;
Tsyrlin, Vitaly A. ;
Greenberg, Barry H. ;
Mayet, Jamil ;
Francis, Darrel P. ;
Shaburishvili, Tamaz ;
Monaghan, Mark ;
Saltzberg, Mitchell ;
Neyses, Ludwig ;
Wasserman, Scott M. ;
Lee, Jacqueline H. ;
Saikali, Khalil G. ;
Clarke, Cyril P. ;
Goldman, Jonathan H. ;
Wolff, Andrew A. ;
Malik, Fady I. .
LANCET, 2011, 378 (9792) :676-683